Through our work on both the hookworm and schistosomiasis vaccines, the Vaccine Development Program has built the necessary technical and academic infrastructure for successful research, development, and clinical testing for future vaccine candidates. We employ a comprehensive approach that manages the development of complex recombinant biologics from initial research to product delivery and use, and our expert team of researchers and medical professionals can develop a customized vaccine program tailored to a specific vaccine candidate as needed.